MI Tumor Seek Hybrid™ is a laboratory developed test (LDT) that simultaneously captures both DNA and RNA and performs high-throughput Next-Generation Sequencing (NGS). Typically, DNA and RNA analysis by NGS requires two separate testing processes, which may require more tissue and more time. By combining Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) of 23,000+ genes into one assay, however, MI Tumor Seek Hybrid provides a comprehensive molecular blueprint that saves tissue without compromising results. The results also include AI signatures Caris GPSai (CUP cases) and Caris FOLFIRSTai (mCRC cases) to help confirm diagnosis and improve therapy selection.

This test provides actionable results to guide clinical decisions in easy-to-interpret report:

• Results with Therapy Associations – Easy to understand biomarker-therapy associations specific to your patient.
• Therapies with Potential Benefit/Lack of Benefit – Therapies with potential benefit are noted in green while lack of benefit is noted in red.
• Important Notes – Significant information about drug/biomarker associations and comments from Caris pathologists and molecular geneticists, if applicable.
• Cancer-Type Relevant Biomarkers – Pre-defined biomarkers whose results will show regardless of presence or absence of an alteration.
• Clinical Trials – Clinical trial information, including Right-In-Time Clinical Trials, can be found in the report.

Product Availability: MI Tumor Seek Hybrid (LDT) is performed as an automatic reflex when MI Cancer Seek™ (CDx) is ordered but does not meet specimen requirements.

PRODUCT SUMMARY

NGS + AI + Molecular Signatures